News

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.

Revenue reached $14.45 billion, up 5% year-over-year, as oncology and other recently launched products offset steep declines in COVID products

Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q1 CY2026, with sales up 5.4% year on year to $14.45 billion. On the other hand, the company’s full-year revenue guidance of $61 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP profit of $0.75 per share was 3.9% above analysts’ consensus estimates.

Pfizer CEO Albert Bourla and Accenture CEO Julie Sweet discuss how they’re using AI to transform their work. Watch the full episode of The 1 on 1 with CNN at CNN.com/the1on1.

Pfizer (PFE) delivered earnings and revenue surprises of +5.63% and +4.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- Pfizer Inc. (NYSE:PFE) reported first-quarter earnings that exceeded Wall Street expectations, driven by strong performance from its recently launched and acquired products portfolio.

The company said it would exit operations at some manufacturing plants in Germany and Singapore, and cut 1,860 positions in total.

US equity futures were trending higher on Tuesday as traders await a fresh batch of corporate earnin

Pfizer shares rose slightly in premarket trading after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook. The drugmaker posted adjusted earnings of 75 cents a share, ahead of the 72 cents Wall Street had forecast. Pfizer reaffirmed its full-year guidance, which it initially provided in December.

Earnings season revs up the next few days as investors will hear from big companies including Advanced Micro Devices, CoreWeave, Pfizer and McDonald's. Data on the U.S. jobs market will also be watched closely, culminating in April nonfarm payroll numbers Friday.

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors should know.

The markets got an unwelcome reminder today that the war in Iran isn’t over, clouding a picture that’s recently been dominated by sunny earnings reports. On Monday, the Dow Jones Industrial Average lost 557 points, or 1.1%, while the S&P 500 declined 0.4% and the Nasdaq Composite slipped 0.2%; the latter two had closed out last week at fresh highs. The war in the Middle East, which Wall Street had all but ignored in recent weeks, flared back into view on Monday.

Asking for a Trend Host Josh Lipton previews several of the biggest stories to come tomorrow, Tuesday, May 5, including earnings results from Advanced Micro Devices (AMD), Pfizer (PFE), and Anheuser-Busch Inbev (BUD); fresh labor data in the form of the latest Job Openings and Labor Turnover Survey (JOLTS) report; and commentary from Federal Reserve Vice Chair for Supervision Michelle Bowman and Governor Michael Barr.

The S&P 500 and the Nasdaq retreated from record highs as oil prices jumped amid signs that the Midd

Pfizer Inc. will release earnings for its third quarter before the opening bell on Tuesday, May 5. Analysts expect the pharmaceutical company to report quarterly earnings of 72 cents per share. That’s down from 92 cents per share in the year-ago period. Benzinga Pro puts the consensus estimate for Pfizer's quarterly revenue at $13.8 billion. Pfizer reported $13.71 billion last year. With the recent buzz around the company, some investors are eyeing potential gains from its dividends. Currently,

Pfizer Inc. (NYSE:PFE) was among the stocks on Jim Cramer’s radar on Mad Money as he discussed the upcoming earnings. Cramer noted that the stock was cheap with a good yield, as he remarked: Hey, can Pfizer break out of its multi-year rut? Now, a lot depends on the presentation because I haven’t seen any […]

US benchmark equity indexes were lower intraday and oil prices jumped as fighting in the Iran war fl

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs. Moderna leaned on cost cuts and international expansion to soften a steep COVID revenue cliff. Two very different pharma stories, both shaped by life ... Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era

May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut

Eli Lilly stock toppled Monday after a patient taking its new weight-loss pill, Foundayo, experienced liver failure.

The benchmark US stock measures were mostly pointing lower before the opening bell Monday as investo

It looks like Pfizer Inc. ( NYSE:PFE ) is about to go ex-dividend in the next three days. The ex-dividend date is one...

Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.

Investors won’t get too much of a respite from a big week trading the AI boom, with Palantir, Advanced Micro Devices, and CoreWeave reporting earnings. A bevy of data about the U.S. jobs market will also be watched closely, culminating in April nonfarm payroll numbers Friday.

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

ON Semiconductor, Pfizer, Uber, McDonald’s, and many more will report earnings this week. Economic releases will include the April jobs report and purchasing managers index.

Pfizer Inc. (NYSE:PFE) ranks among the best low-risk investments in May 2026. On April 13, Guggenheim reaffirmed a Buy rating and a $36 price target for Pfizer Inc. (NYSE:PFE) as the firm revised its financial forecast ahead of the company’s Q1 earnings announcement on May 5. The firm anticipates first-quarter revenues of around $13.8 billion, […]

Novavax (NVAX) is in focus after outlining a move toward a licensing and royalty model, supported by partnerships with Sanofi and Pfizer, while investors watch for a Phase 3 COVID influenza combo readout. See our latest analysis for Novavax. The licensing pivot and upcoming COVID influenza combo catalyst come after a mixed period for investors, with a 12.76% year-to-date share price return alongside a 25.43% one-year total shareholder return, but a very large five-year total shareholder loss...

Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo Nordisk's faster initial prescription ramp for its oral therapy. While early volume data favors the competitor’s established brand capture, the central equity debate remains focused on the friction between high demand and pricing pressure from pharmacy benefit managers. Critics highlight dropping reali

Blue-chip stocks are shares of large, well-established, financially stable companies with a consistent and reliable performance history. They are often considered less risky and are a popular choice for long-term investors. Additionally, nearly all leaders in the category pay dependable, recurring dividends each quarter, regardless of the state of the economy. The term “blue chip” ... 5 Quality Passive Income Blue-Chips That All Yield 5% and More Safely